Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial.

dc.contributor	Казанский федеральный университет
dc.contributor.author	Nurmeev Ildar Nailevich
dc.date.accessioned	2025-12-12T07:49:39Z
dc.date.available	2025-12-12T07:49:39Z
dc.date.issued	2019
dc.identifier.citation	Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial / Christoph Male, Anthonie W. A. Lensing, Joseph S. Palumbo, Riten Kumar, Ildar Nurmeev et al. // Lancet Haematol. - 2019 Nov 4. - pii: S2352-3026(19)30219-4. - doi: 10.1016/S2352-3026(19)30219-4
dc.identifier.uri	https://dspace.kpfu.ru/xmlui/handle/net/185551
dc.description.abstract	Статья о результатах применения препарата ривароксабан у детей с венозными тромбозами, в международной коллаборации ученых.
dc.language.iso	en
dc.relation.ispartofseries	LANCET HEMATOLOGY
dc.rights	открытый доступ
dc.subject	children
dc.subject	thrombosis
dc.subject	treatment
dc.title	Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial.
dc.type	Article
dc.contributor.org	Институт фундаментальной медицины и биологии
dc.description.pages	18-27
dc.relation.ispartofseries-volume	4
dc.pub-id	321407
dc.identifier.doi	10.1016/S2352-3026(19)30219-4